Regenxbio Inc
RGNX
$11.79
Closing
▲3.42%
1D
▼-34.32%
YTD
RGNX
BBG007Z9V5C7
Market cap
$582.70M
52 week high
$28.80
52 week low
$10.50
Volume
100,462
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$582.70M
Analysts' Rating
BUY
Price Target (Mean)
38.08
Total Analysts
10
P/E
Operating Margin
-251.34%
Beta
1.21
Revenue Growth
11.60%
52 week high
$28.80
52 week low
$10.50
Div. Yield
%
EPS Growth
-23.91
Company Profile
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
